|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2000-1-28
|
|
pubmed:abstractText |
Yttrium-90 ibritumomab tiuxetan (IDEC-Y2B8) is a murine immunoglobulin G1 kappa monoclonal antibody that covalently binds MX-DTPA (tiuxetan), which chelates the radioisotope yttrium-90. The antibody targets CD20, a B-lymphocyte antigen. A multicenter phase I/II trial was conducted to compare two doses of unlabeled rituximab given before radiolabeled antibody, to determine the maximum-tolerated single dose of IDEC-Y2B8 that could be administered without stem-cell support, and to evaluate safety and efficacy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:EmmanouilidesCC,
pubmed-author:GordonL ILI,
pubmed-author:Grillo-LópezA JAJ,
pubmed-author:GutheilJJ,
pubmed-author:JanakiramanNN,
pubmed-author:ParkerEE,
pubmed-author:RaubitschekAA,
pubmed-author:SchilderR JRJ,
pubmed-author:SilvermanD HDH,
pubmed-author:SpiesSS,
pubmed-author:WhiteC ACA,
pubmed-author:WisemanG AGA,
pubmed-author:WitzigT ETE
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3793-803
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:10577851-Adolescent,
pubmed-meshheading:10577851-Adult,
pubmed-meshheading:10577851-Antibodies, Monoclonal,
pubmed-meshheading:10577851-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:10577851-Antigens, CD20,
pubmed-meshheading:10577851-Antineoplastic Agents,
pubmed-meshheading:10577851-B-Lymphocytes,
pubmed-meshheading:10577851-Female,
pubmed-meshheading:10577851-Humans,
pubmed-meshheading:10577851-Lymphoma, Non-Hodgkin,
pubmed-meshheading:10577851-Male,
pubmed-meshheading:10577851-Middle Aged,
pubmed-meshheading:10577851-Radioimmunotherapy,
pubmed-meshheading:10577851-Recurrence,
pubmed-meshheading:10577851-Yttrium Radioisotopes
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
|
|
pubmed:affiliation |
Divisions of Hematology and Nuclear Medicine, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
